NXL

Further analysis of ADAS-Cog data from the Company's randomized, sham-controlled clinical trial — previously published in the Journal of Alzheimer's Disease and in Radiology — identifies specific improvements in cognitive domains associated with memory in Alzheimer's patients

HOUSTON, TX, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), announces that its board of directors has approved a 1-for-30 reverse stock split of the Company's common stock, to ensure continued compliance with the Nasdaq bid-price rule. The Company's stockholders approved future reverse stock splits, their timing, and granted the board of directors authority to determine future exact split ratios.

Dr. Victor Fontenelle Bastos de Lima, an investigator on Nexalin's recently completed Brazilian clinical study, received the Young Researcher Award at BRAIN 2026 – Congress on Brain, Behavior and Emotions, held in Porto Alegre, Brazil

Accepted abstracts showcase Nexalin's proprietary DIFS™ 15 mA 77.5 Hz treatment platform and clinical improvements across anxiety, depression, insomnia and quality of life

Study using Nexalin's proprietary DIFS™ 15 mA 77.5 Hz treatment platform demonstrated rapid, large-magnitude improvements in anxiety and depression with benefits maintained at 8-week follow-up

Newly issued U.S. patent expected to provide core intellectual property protection through 2042, further strengthening Nexalin's proprietary position in non-invasive frequency-based deep-brain neurostimulation

U.S. House Appropriations Committee report language directs VA to support additional research evaluating non-invasive deep brain neurostimulation technologies for veterans with treatment-resistant traumatic brain injury

Acquisition gives Nexalin control of AI-integrated remote patient-monitoring, clinical data-capture and virtual-care infrastructure already deployed at UCSD Acquisition gives Nexalin control of AI-integrated remote patient-monitoring, clinical data-capture and virtual-care infrastructure already deployed at UCSD

Publication reports statistically significant improvement in sleep quality following treatment with Nexalin's 15 mA, 77.5 Hz stimulation approach, with no meaningful improvement in the sham group

160-participant, triple-blinded, sham-controlled study designed to support planned De Novo FDA submission for moderate-to-severe insomnia 160-participant, triple-blinded, sham-controlled study designed to support planned De Novo FDA submission for moderate-to-severe insomnia